Immunological Phenotype and Prognosis of T-Lineage Malignancy in Children
The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in children. Twenty-nine patients from July 1984 to December 1991 were included in this study. Ten patients were treated with the regimen without...
Saved in:
| Published in | The Japanese Journal of Pediatric Hematology Vol. 7; no. 1; pp. 41 - 46 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY
1993
特定非営利活動法人 日本小児血液・がん学会 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0913-8706 1884-4723 |
| DOI | 10.11412/jjph1987.7.41 |
Cover
| Abstract | The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in children. Twenty-nine patients from July 1984 to December 1991 were included in this study. Ten patients were treated with the regimen without HDCA (Group A), 9 received single HDCA intensification (Group B) and 10 were treated with cyclic HDCA intensifications (Group C). Disease-free survival (DFS) rates at 48 months were 48%, 38.1% and 71%, respectively. Although these values were not significantly different, cyclic HDCA intensifications seem to be effective for T-ALL and NHL in children, because only 2 patients of Group C relapsed. The phenotype of the samples from Group B and C was divided into 3 groups, i.e., CD3 + group; CD3-, CD4+ and/or CD8+group; and CD3-, CD4-and CD8-group. The patients whose leukemic cells expressed CD3 had a favorable prognosis, and the patients with CD3-, CD4-and CD8-had the worst. Further study is needed to clarify whether the phenotype remains a prognostic factor in patients treated with very intensive therapies or not. |
|---|---|
| AbstractList | The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in children. Twenty-nine patients from July 1984 to December 1991 were included in this study. Ten patients were treated with the regimen without HDCA (Group A), 9 received single HDCA intensification (Group B) and 10 were treated with cyclic HDCA intensifications (Group C). Disease-free survival (DFS) rates at 48 months were 48%, 38.1% and 71%, respectively. Although these values were not significantly different, cyclic HDCA intensifications seem to be effective for T-ALL and NHL in children, because only 2 patients of Group C relapsed. The phenotype of the samples from Group B and C was divided into 3 groups, i.e., CD3 + group; CD3-, CD4+ and/or CD8+group; and CD3-, CD4-and CD8-group. The patients whose leukemic cells expressed CD3 had a favorable prognosis, and the patients with CD3-, CD4-and CD8-had the worst. Further study is needed to clarify whether the phenotype remains a prognostic factor in patients treated with very intensive therapies or not.
1984年7月から1991年12月までにT系ALLあるいはNHLと診断した29例を対象として, キロサイド大量療法 (HDCA) の有用性とphenotypeと予後の関連について検討した.HDCAを含まないプロトコールで治療された群 (A群) が10例, HDCAの強化療法を1回受けた群 (B群) が9例, HDCA強化療法を定期的に施行された群 (C群) が10例であった.各群の48カ月の無病生存率は各々48%, 38.1%, 70%であり, 有意差は認められなかった.しかし, C群では再発はわずか2例であり, HDCAの定期的な強化療法はT系ALL/NHLに有用であると思われた.B+C群で, phenotypeからCD3, CD4, CD8全て陰性例, CD3陰性でCD4あるいはCD8陽性例, CD3陽性例の3群にわけて予後を検討した.CD3陽性例が最も予後良好で, CD3, CD4, CD8陰性例は予後不良であった (p<0.05).Phenotypeが独立予後因子となりうるかどうかを明らかにするためには, 今後C群のみでのphenotypeと予後の検討が必要であろう. The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in children. Twenty-nine patients from July 1984 to December 1991 were included in this study. Ten patients were treated with the regimen without HDCA (Group A), 9 received single HDCA intensification (Group B) and 10 were treated with cyclic HDCA intensifications (Group C). Disease-free survival (DFS) rates at 48 months were 48%, 38.1% and 71%, respectively. Although these values were not significantly different, cyclic HDCA intensifications seem to be effective for T-ALL and NHL in children, because only 2 patients of Group C relapsed. The phenotype of the samples from Group B and C was divided into 3 groups, i.e., CD3 + group; CD3-, CD4+ and/or CD8+group; and CD3-, CD4-and CD8-group. The patients whose leukemic cells expressed CD3 had a favorable prognosis, and the patients with CD3-, CD4-and CD8-had the worst. Further study is needed to clarify whether the phenotype remains a prognostic factor in patients treated with very intensive therapies or not. |
| Author | TAWA, Akio KAW-HA, Keisei ISHIHARA, Shigehiko KURAHASHI, Hiroki HARA, Junichi SAKATA, Naoki KOUDERA, Urara SAKO, Masanori YUMURA-YAGI, Keiko INOUE, Masami OSUGI, Yuko KONISHI, Syouzaburou |
| Author_FL | 河 敬世 多和 昭雄 圀府寺 美 倉橋 浩樹 大杉 夕子 坂田 尚己 小西 省三郎 迫 正廣 井上 雅美 勇村 啓子 原 純一 石原 重彦 |
| Author_FL_xml | – sequence: 1 fullname: 勇村 啓子 – sequence: 2 fullname: 原 純一 – sequence: 3 fullname: 倉橋 浩樹 – sequence: 4 fullname: 大杉 夕子 – sequence: 5 fullname: 坂田 尚己 – sequence: 6 fullname: 井上 雅美 – sequence: 7 fullname: 石原 重彦 – sequence: 8 fullname: 多和 昭雄 – sequence: 9 fullname: 圀府寺 美 – sequence: 10 fullname: 小西 省三郎 – sequence: 11 fullname: 迫 正廣 – sequence: 12 fullname: 河 敬世 |
| Author_xml | – sequence: 1 fullname: INOUE, Masami organization: Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health – sequence: 1 fullname: HARA, Junichi organization: Department of Pediatrics, Osaka University Medical School – sequence: 1 fullname: SAKATA, Naoki organization: Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health – sequence: 1 fullname: TAWA, Akio organization: Department of Pediatrics, Osaka University Medical School – sequence: 1 fullname: KAW-HA, Keisei organization: Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health – sequence: 1 fullname: ISHIHARA, Shigehiko organization: Department of Pediatrics, Osaka University Medical School – sequence: 1 fullname: OSUGI, Yuko organization: Department of Pediatrics, Osaka University Medical School – sequence: 1 fullname: KOUDERA, Urara organization: Department of Pediatrics, Kansai Medical College – sequence: 1 fullname: KURAHASHI, Hiroki organization: Division of Clinical Genetics, Department of Medical Genetics, Biological Research Center, Osaka University Medical School – sequence: 1 fullname: YUMURA-YAGI, Keiko organization: Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health – sequence: 1 fullname: KONISHI, Syouzaburou organization: Division of Haematology/Oncology, Children's Medical Center of Osaka City – sequence: 1 fullname: SAKO, Masanori organization: Division of Haematology/Oncology, Children's Medical Center of Osaka City |
| BackLink | https://cir.nii.ac.jp/crid/1390001204342313472$$DView record in CiNii |
| BookMark | eNo9UD1vwjAUtCoqlVLWzh66hr5nO3EyItQPJKoy0Nl6sZ3EUXBQQgf-faFfw90b7nS6d7dsEvvoGbtHWCAqFI9te2iwyPVCLxResSnmuUqUFnLCplCgTHIN2Q2bj2MoAdI8B1B6ytbr_f4z9l1fB0sd3zY-9sfTwXOKjm-Hvo79GEbeV3yXbEL0VHv-Rl2oI0V74iHyVRM6N_h4x64r6kY__70z9vH8tFu9Jpv3l_VquUlaVEok6bkMOKs1gUWNVVoqL8kp7aQAbzNdpBmlmpyrsPRUQloBVCIrpRdFSYWcsYef3BiCseHCKAsAQAFKKiFRXt6eseWPrR2P59LmMIQ9DSdDwzHYzpu_vYw2-A2F_5ptaDA-yi9wI2cJ |
| ContentType | Journal Article |
| Copyright | Copyright Clearance Center, Inc |
| Copyright_xml | – notice: Copyright Clearance Center, Inc |
| DBID | RYH |
| DOI | 10.11412/jjph1987.7.41 |
| DatabaseName | CiNii Complete |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | 小児Ｔ系ｌｅｕｋｅｍｉａ／ｌｙｍｐｈｏｍａのｐｈｅｎｏｔｙｐｅと予後 |
| DocumentTitle_FL | 小児Ｔ系ｌｅｕｋｅｍｉａ／ｌｙｍｐｈｏｍａのｐｈｅｎｏｔｙｐｅと予後 |
| EISSN | 1884-4723 |
| EndPage | 46 |
| ExternalDocumentID | 130004346187 article_jjph1987_7_1_7_1_41_article_char_en |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 RJT RYH |
| ID | FETCH-LOGICAL-j1442-50910dc77a0c171f5b4e3ad47d320ec67956a57addf1beab05f00f26b3e29ba93 |
| ISSN | 0913-8706 |
| IngestDate | Fri Jun 27 00:36:50 EDT 2025 Wed Sep 03 06:29:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j1442-50910dc77a0c171f5b4e3ad47d320ec67956a57addf1beab05f00f26b3e29ba93 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjph1987/7/1/7_1_41/_article/-char/en |
| PageCount | 6 |
| ParticipantIDs | nii_cinii_1390001204342313472 jstage_primary_article_jjph1987_7_1_7_1_41_article_char_en |
| PublicationCentury | 1900 |
| PublicationDate | 1993 |
| PublicationDateYYYYMMDD | 1993-01-01 |
| PublicationDate_xml | – year: 1993 text: 1993 |
| PublicationDecade | 1990 |
| PublicationTitle | The Japanese Journal of Pediatric Hematology |
| PublicationTitleAlternate | J.J.P.H. |
| PublicationTitle_FL | 日本小児血液学会雑誌 J.J.P.H 日小血会誌 |
| PublicationYear | 1993 |
| Publisher | THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY 特定非営利活動法人 日本小児血液・がん学会 |
| Publisher_xml | – name: THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY – name: 特定非営利活動法人 日本小児血液・がん学会 |
| References | 9) Dahl GV, Rivera GK, Look AT, et al : Teniposide plus cytarabine improved outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100,000/mm3. J Clin Oncol 5 : 1015-1021, 1987 2) Weinstein HJ, Cassady R, Levey R : Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1 : 537-541, 1983 13) Yumura-Yagi K, Hara J, Kurahashi H, et al : Clinical significance of CD7-positive stem cell leukmia; a distinct subgroup of mixed lineage leukemia. Cancer 68 : 2273-2280, 1991 5) Yumura-Yagi K, Ishihara S, Hara J, et al : Poor prognosis of mediastinal non Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5) +, CD3-, CD4-, and CD8 -. Cancer 63 : 671-674, 1989 1) Sullivan MP, Boyett J, Pullen J, et al : Pediatric oncology group experience with modified LSA2-L2 therapy in 107 children with non Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 55 : 323-336, 1985 6) Crist WM, Shueter JJ, Falleta J, et al : Clinical features and outcome in childhood T-cell leukemialymphoma according to stage of thymocyte differentiation. : a pediatric oncology group study. Blood 72 : 1891-1897, 1988 15) Pullen DJ, Sullivan MP, Falletta JM, et al : Modified LSA2L2 treatment in 53 children with E-rosette positive T-cell leukemia : results and prognostic factors. Blood 60 : 1159, 1982 14) Yumura-Yagi K, Hara J, Terada N, et al : Analysis of molecular events in leukemic cells arrested at early stage of T-cell differentiation. Blood 74 : 2103-2111, 1989 7) Amylon MD : Treatment of T-lineage acute lymphoblastic leukemia. Hematol/Oncol Clin North Am 4 : 937-949, 1991 12) Hara J, Yumura-Yagi K, Tawa A, et al : Molecular analysis of acute undifferentiated leukemia : two distinct subgroups at the DNA and RNA levels. Blood 74 : 1738-1746, 1989 16) Pui C-H, Ribeiro RC, Hancock MS, et al : Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325 : 1682-1687, 1991 8) Weily JS, Traupin J, Jamieson GP, et al : Cytosine arabinoside transport and T-cell lymphoblastic lymphoma. J Clin Invest 75 : 632-642, 1985 10) 勇村啓子, 河敬世, 石原重彦, 他 : 小児悪性リンパ腫 (Non-Hodgkin's Lymphoma) に対するAra-C大量療法-強化療法ならびにCNS予防としての有用性-.臨床血液 28 : 371-376, 1987 11) Shuster JJ, Falletta LH, Pullen L, et al : Prognostic factor in T-cell acute lymphoblastic leukemia : a pediatric oncology group study. Blood 75 : 166-173, 1990 3) Lauer SJ, Pinkel D, Buchanan GR, et al : Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia; potential selective effect in T-cell leukemia. Cancer 60 : 2366-2371, 1987 4) Pui C-H, Behm FG, Singh B, et al : Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75 : 174-179, 1990 |
| References_xml | – reference: 6) Crist WM, Shueter JJ, Falleta J, et al : Clinical features and outcome in childhood T-cell leukemialymphoma according to stage of thymocyte differentiation. : a pediatric oncology group study. Blood 72 : 1891-1897, 1988 – reference: 2) Weinstein HJ, Cassady R, Levey R : Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1 : 537-541, 1983 – reference: 16) Pui C-H, Ribeiro RC, Hancock MS, et al : Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325 : 1682-1687, 1991 – reference: 13) Yumura-Yagi K, Hara J, Kurahashi H, et al : Clinical significance of CD7-positive stem cell leukmia; a distinct subgroup of mixed lineage leukemia. Cancer 68 : 2273-2280, 1991 – reference: 1) Sullivan MP, Boyett J, Pullen J, et al : Pediatric oncology group experience with modified LSA2-L2 therapy in 107 children with non Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 55 : 323-336, 1985 – reference: 4) Pui C-H, Behm FG, Singh B, et al : Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75 : 174-179, 1990 – reference: 3) Lauer SJ, Pinkel D, Buchanan GR, et al : Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia; potential selective effect in T-cell leukemia. Cancer 60 : 2366-2371, 1987 – reference: 8) Weily JS, Traupin J, Jamieson GP, et al : Cytosine arabinoside transport and T-cell lymphoblastic lymphoma. J Clin Invest 75 : 632-642, 1985 – reference: 15) Pullen DJ, Sullivan MP, Falletta JM, et al : Modified LSA2L2 treatment in 53 children with E-rosette positive T-cell leukemia : results and prognostic factors. Blood 60 : 1159, 1982 – reference: 14) Yumura-Yagi K, Hara J, Terada N, et al : Analysis of molecular events in leukemic cells arrested at early stage of T-cell differentiation. Blood 74 : 2103-2111, 1989 – reference: 7) Amylon MD : Treatment of T-lineage acute lymphoblastic leukemia. Hematol/Oncol Clin North Am 4 : 937-949, 1991 – reference: 9) Dahl GV, Rivera GK, Look AT, et al : Teniposide plus cytarabine improved outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100,000/mm3. J Clin Oncol 5 : 1015-1021, 1987 – reference: 10) 勇村啓子, 河敬世, 石原重彦, 他 : 小児悪性リンパ腫 (Non-Hodgkin's Lymphoma) に対するAra-C大量療法-強化療法ならびにCNS予防としての有用性-.臨床血液 28 : 371-376, 1987 – reference: 12) Hara J, Yumura-Yagi K, Tawa A, et al : Molecular analysis of acute undifferentiated leukemia : two distinct subgroups at the DNA and RNA levels. Blood 74 : 1738-1746, 1989 – reference: 5) Yumura-Yagi K, Ishihara S, Hara J, et al : Poor prognosis of mediastinal non Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5) +, CD3-, CD4-, and CD8 -. Cancer 63 : 671-674, 1989 – reference: 11) Shuster JJ, Falletta LH, Pullen L, et al : Prognostic factor in T-cell acute lymphoblastic leukemia : a pediatric oncology group study. Blood 75 : 166-173, 1990 |
| SSID | ssib005880047 ssj0003236711 ssib053390765 ssib002003923 ssib058493933 |
| Score | 1.3805319 |
| Snippet | The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in... |
| SourceID | nii jstage |
| SourceType | Publisher |
| StartPage | 41 |
| SubjectTerms | HDCA phenotype T-lineage ALL/NHL |
| Title | Immunological Phenotype and Prognosis of T-Lineage Malignancy in Children |
| URI | https://www.jstage.jst.go.jp/article/jjph1987/7/1/7_1_41/_article/-char/en https://cir.nii.ac.jp/crid/1390001204342313472 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | The Japanese Journal of Pediatric Hematology, 1993/02/28, Vol.7(1), pp.41-46 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Pb9MwFLa6ceGCQIAYMOQDN5SSH27c7GaNoGZTu7KlYpyiOLHXZCKdRnfhL-PP4704dVONA4NDrcppo8Tv0_Pn5_c9E_J-zHNXRX7pcO1zh-XKc2QgtROEuvRDLTlrj2SZzsLJgp1cji4Hg1-9rKW7tRwWP_-oK_kXq0If2BVVsg-wrL0pdMB3sC-0YGFo_8rGCYo7rPeaL1WzakOqnQIAc-hMuZHUgTWnwvScKfDuKyyyYfR-nZS7T1FbsRhMoXg05YceX7WHesBUBTR3JxyfzM4WsZH-_Mi_VxYr4lwY6UdTFUvbfSFORSqMb19d2-5UfG07xbXJDTPBCEz9s8DB_KQTMRez-CLGIg5JnH7DvKV5_CkR6TkgahJPRdpujsGwns2Ot_tkXTzSCxzcdDUTk_HG4zFzGDeC5I275vdQaVyvqZ_VTeImrHl_emAe1put65slBluGfLj5107J7c6g2eZ3Gc-89sO8bHMNRXGAwT3yyOfcw2TS0y-9hRtqnnvEawRusre_CRw7cvl2fxlYYBREHfFGDhFgYb328Gg7Ll3FUXyFjzsvANyphpUElojYa6qqR4_Sp-RJhxMqzHM_I4M6f06SHYBSC1AKAKUWoHSlqQUo3QKUVg3dAPQFWXyO0-OJ053d4dSwRPedloeWBQdXUHjc0yPJVJCXjJeB76oi5LAuz0ccZlftSZXDEGjX1X4oA-VHMo-Cl2S_WTXqFaEul4VbRHDV1SwKgT7lPFRsrJmfB0XpHpAj8_7ZjSnQkj3AfgfkEMYsKypsYTXURmZdhnUxUWTtv_6fm78hj01-LEbs3pL99e2dOgQOu5bvWrj8BidXlcA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunological+Phenotype+and+Prognosis+of+T-Lineage+Malignancy+in+Children&rft.jtitle=The+Japanese+Journal+of+Pediatric+Hematology&rft.au=INOUE%2C+Masami&rft.au=HARA%2C+Junichi&rft.au=SAKATA%2C+Naoki&rft.au=TAWA%2C+Akio&rft.date=1993&rft.pub=THE+JAPANESE+SOCIETY+OF+PEDIATRIC+HEMATOLOGY%2FONCOLOGY&rft.issn=0913-8706&rft.eissn=1884-4723&rft.volume=7&rft.issue=1&rft.spage=41&rft.epage=46&rft_id=info:doi/10.11412%2Fjjph1987.7.41&rft.externalDocID=article_jjph1987_7_1_7_1_41_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0913-8706&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0913-8706&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0913-8706&client=summon |